Ticagrelor better than clopidogrel for ACS

In this trial of 13,408 patients with ACS undergoing PCI, they were randomized to clopidogrel (300-600mg load followed by 75mg daily) or ticagrelor (180 mg load followed by 90mg BID) for 6-12 months. At 1 year, the combined outcome (CV death, MI, CVA) occurred significantly less often in the ticagrelor group (9% vs 11%) with no difference in bleeding. Ticagrelor will likely replace clopidogrel for post-ACS prevention of CV death/MI/CVA (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment